论文部分内容阅读
目的 分析胸腺肽 α1(日达仙 )在长期机械通气患者预防呼吸机相关肺炎的应用价值。方法 对 1例高龄长期应用机械通气患者给予胸腺肽 α11.6 mg,皮下注射 ,每周两次 ,治疗 1年余 ,分析应用胸腺肽 α1后 0 .5年及0 .5～ 1年时间内与未应用胸腺肽 α1两个 0 .5年时间的体温变化、肺部感染次数、痰培养结果及病重、病危天数、药费、检查费等 ,并对血常规、血生化结果进行比较。结果 应用胸腺肽 α1后体温升高天数减少 ;呼吸机相关肺炎发生次数减少 ;对抗生素不敏感的嗜麦芽寡养单胞菌消失 ,各项检查次数减少 ,血尿素氮恢复正常 ,病情处于平稳状态。结论 长期机械通气患者应用胸腺肽 α1治疗可减少呼吸机相关肺炎次数 ,改善患者全身状况 ,减少医疗费用。
Objective To analyze the value of thymosin α1 (daily dose) in prevention of ventilator-associated pneumonia in patients with long-term mechanical ventilation. Methods A long-term long-term use of mechanical ventilation patients given thymosin α11.6 mg, subcutaneous injection twice a week for more than 1 year after treatment, analysis of thymosin α1 after 0.5 and 0.5-1 years of time and without Thymosin α1 two 0.5 years of temperature changes, the number of lung infections, sputum culture results and ill, critically ill days, drugs, examination fees, and blood, blood biochemical results were compared. Results After thymosin α1 was applied, the number of days of hypothermia decreased, the number of ventilator-associated pneumonia decreased, antibiotic-insensitive Stenotrophomonas maltophilia disappeared, the number of examinations decreased, blood urea nitrogen returned to normal, and the condition was stable. Conclusion Long-term mechanical ventilation in patients with thymosin α1 treatment can reduce the number of ventilator-associated pneumonia, improve the general condition of patients and reduce medical costs.